Hemogenyx Pharmaceuticals PLC Total Voting Rights
January 31 2025 - 3:35AM
RNS Regulatory News
RNS Number : 4652V
Hemogenyx Pharmaceuticals PLC
31 January 2025
31 January 2025
Hemogenyx Pharmaceuticals
plc
("Hemogenyx
Pharmaceuticals" or the "Company")
Total Voting Rights
Hemogenyx Pharmaceuticals plc (LSE:
HEMO), the biopharmaceutical group developing new therapies and
treatments for blood diseases, announces that the total issued
share capital of the Company as at 31 January 2025 consists of
3,604,539 ordinary shares of 1 pence each, none of which are held
in treasury. Therefore, the total number of voting rights in the
Company is 3,604,539.
The figure of
3,604,539 ordinary shares may be used by shareholders of the
Company as the denominator for the calculations by which they will
determine if they are required to notify their investment in, or a
change in their interest in, the share capital of the Company under
the Financial Conduct Authority's Disclosure Guidance and
Transparency Rules.
Enquiries:
|
Hemogenyx Pharmaceuticals plc
|
https://hemogenyx.com
|
|
Dr Vladislav Sandler, Chief
Executive Officer & Co-Founder
|
headquarters@hemogenyx.com
|
|
Peter Redmond, Director
|
peter.redmond@hemogenyx.com
|
|
|
|
|
SP
Angel Corporate Finance LLP
|
Tel: +44 (0)20 3470 0470
|
|
Matthew Johnson, Vadim Alexandre,
Adam Cowl
|
|
|
|
|
|
Peterhouse Capital Limited
|
Tel: +44 (0)20 7469 0930
|
|
Lucy Williams, Duncan Vasey, Charles
Goodfellow
|
|
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
TVREANFFDDLSEEA
Hemogenyx Pharmaceuticals (LSE:HEMO)
Historical Stock Chart
From Jan 2025 to Feb 2025
Hemogenyx Pharmaceuticals (LSE:HEMO)
Historical Stock Chart
From Feb 2024 to Feb 2025
